VXRT - 2 Contenders in the Coronavirus Vaccine Market -- Are They Buys?
Many companies that successfully developed effective coronavirus vaccines are reaping the benefits and generating millions -- sometimes billions -- in sales from their products. However, other players are still looking to get in the game.
Two notable companies still hoping to make a dent in this market include Inovio Pharmaceuticals (NASDAQ: INO) and Vaxart (NASDAQ: VXRT) . Can these two latecomers still profit from their coronavirus-related efforts? Let's discuss whether it is worth it for investors to bet on these companies.
Once considered a leader in the hunt for a coronavirus vaccine, Inovio Pharmaceuticals ran into several regulatory headwinds. For instance, the company's phase 2/3 clinical trial for its candidate, INO-4800, was put on clinical hold by authorities in the U.S. Regulators had questions regarding Inovio's Cellectra 2000, a proprietary handheld device that looks like an electric toothbrush, and which the biotech uses to administer the vaccine.
For further details see:
2 Contenders in the Coronavirus Vaccine Market -- Are They Buys?